• Managing investment activities including R&D development, early-stage start-ups, in-licensing, collaboration and new venture incubation outside China, establishing and maintaining relationship of C-suite executives of start-ups• Partnering with internal stakeholders, including H.R., patent, finance and other Fapon’s new venture facilities to conduct due diligence and to develop partnering or investing opportunities with academic institutes and early-stage start-ups• Leading valuation, out-licensing and co-development initiatives for FP002 (an oncology biologic) and R1464 (a Covid19 nanobody) in the United States• Developed connections with the BD team from four major pharmaceutical companies• Completed due diligence of 11 start-ups in mRNA therapeutics, drug delivery system, microfluid platform, single-cell sequencing, AI-based digital health, and AI-based biotechnology• Conducted systemic technology review and market research, talent mapping in anti-aging, mRNA, drug delivery system, microfluid platform, single-cell sequencing, AI-based digital health, and AI-based biotechnology• Driving business development and operation of a Fapon’s U.S. start-up (an AI based diagnostic company), conducting recruitment of industry advisors and market research, structuring incentive plans and MSA capability• Closed an agreement on establishing a joined-venture on image-based AI protein design with Shang Hai Xiaotong University

Delivered advanced analytics and data solutions for different internal stakeholders, including operation, clinical development and supply chainCollaborated with business leaders from IT, finance, H.R., and functional leaders in different business units to identify, advise and develop advanced analytics and insightsOptimized operation and analytical capabilities of the global supply chain through delivering analysis and automated visualization tool in tableau using statistical modeling and data engineering, reducing the cost of inventory tracking by approximately 10 million USD

• Advised multiple academic institutions on sampling method, sampling size, and experimental design for publications• Drafted data collection management and statistical analysis plan (e.g. T-test, ANOVA, Chi-square, post hoc test)

Facilitated external contracting of a data vendor for developing a new digital platform based on the real-world data (RWD), managed UAT, data quality report, end-user training and system deploymentImproved the accuracy and interpretability of rNPV model for valuation of oncology pipelines through Monte Carlo stimulation worked with the business development and finance team to develop model-based revenue forecast and pipeline valuationResolved a critical site activation issue through an analysis of standard care drug supply using R-coded RWD and competitive intelligence data, adding 25 additional sites to the studyEvaluated two partnership opportunities on developing artificial intelligence-based drug development for the oncology early development team, facilitated communication between external partners and R&D functional leaders

• Improved the accuracy and interpretability of rNPV model for valuation of oncology pipelines through Monte Carlo stimulation worked with the business development and finance team to develop model-based revenue forecast and pipeline valuation• Resolved a critical site activation issue through an analysis of standard care drug supply using R-coded RWD and competitive intelligence data, adding 25 additional sites to the study• Evaluated two partnership opportunities on developing artificial intelligence-based drug development for the oncology early development team, facilitated communication between external partners and R&D functional leaders• Facilitated R&D functional leaders’ decisions on optimizing resource utilization through automating monthly manual reporting and tracking process for headcount, resource utilization, budget, portfolio operation, R&D milestone, and training compliance• Conducted in-depth due diligence, clinical characterization, constraints evaluation, and competitiveness assessment to improve clinical trial placement, recruitment, and monitoring • Improved generic name application through creating tools for timeline monitoring, facilitating communication with USAN officials, documenting frequently asked questions, and publishing standard workflow• Developed semi-automated global clinical trial operation covid19 related FAQ website using NLP modeling in R

• Utilized a negative binomial regression model to estimate the minimum program length to improve the health condition of diabetic indigenous population• Led survey research of the prevalence of diabetes in rural Guatemala with medical specialists and community healthcare workers, drafted funding proposal based on the survey results• Oversaw organizational planning, project execution and resource management, forecasting and monitoring operational cost

• Provided marketing solutions and business strategies to pharmaceutical companies through building oncology related advanced statistical analysis with RWD data (i.e. patient DX/RX claim, EMR, prescription) • Partnered with the sales team and clinical team in discovering new business opportunities, developing business scope, presenting analysis, and managing the client relationship• Supervised three offshore developers, delivering 20-30 ongoing projects monthly (e.g., market sizing and segmentation, drug persistency and compliance, predictive modeling, physician targeting, HEOR) and contributing $2 million in annualrevenue in 2017• Created new revenue stream through a new predictive modeling by machine learning, contributing $200,000 sales in 2017 and $500,000 sales in 2018

Teaching Assistant of Course “Statistical Computing with Statistical Analysis System (SAS)”; taught one lecture on “ categorical data analysis ” to 39 graduate students

Executed a portfolio reassessment based on a regression analysis on time to new drug approvalBuild survey questionnaires for customer satisfaction assessment